At Lightsense, we’re breaking new ground in public health

That’s because we are translating expensive, tabletop spectrometer instrumentation into miniaturized, handheld platforms - all with AI/ML powered optical detection technology that can serve a wide range of analytical applications.

Our focus is on utilizing this new class of tools to help solve some major problems in public health - such as detecting fentanyl and other illicit drugs in the opioid epidemic, detecting viral pathogens in the COVID-19 pandemic, as well as detecting bacterial pathogens in the food safety field.

We are a diverse and experienced group of successful scientists, engineers, and entrepreneurs focused on using modern optics techniques (especially miniaturized spectroscopy), advances in sensors and machine learning to attack problems related to public health in new, insightful ways.

Public Health is facing some critical problems

In all the critical areas of public health - the common thread is that detection and testing solutions need to be faster, less expensive and more accurate. 

Meet the Multispectral Point-of-Need Analyzers

Lightsense has developed a multi-spectral technology platform, the patented “Enhanced Photodetection Spectroscopy” (EPS) , a radical new spectroscopy architecture, for chemical, molecular and pathogen identification. 

Our devices can address critical analytical and detection problems in multiple areas of public health -  like rapid detection of illicit drugs, rapid screening for viral/bacterial pathogens, and monitoring bacterial pathogens in various parts of the food supply chain.

When it comes to the science: Spectroscopy uses light of many wavelengths to analyze objects or chemical compounds. This light energy interrogates the molecule of interest and produces a spectral response - creating what scientists call a “spectral fingerprint.” This fingerprint contains large amounts of data, and with our multispectral approach, data fusion and analysis, we can increase sensitivity. AI/ML can be used to detect known patterns and monitor samples, like in the three mentioned areas of public health, above, where we are creating solutions and partnerships.  

Machine Learning is a critical feature in our technology. It not only uses algorithms to detect patterns otherwise not visible and predict outcomes, EPS spectra contain large amounts of data which are aggregated in Cloud databases, allowing monetizing them as a new subscription service. 

Our business model includes both hardware and SaaS components. What makes us unique is a radical new and patented spectroscopy that integrates three or more individual spectroscopies with data fusion and machine learning analytics. Our miniaturization technology allows the construction of integrated small and handheld instruments. 

Our IP can also be licensed along with products in specific domain applications. Unique solutions can be crafted for individual partners and customers justifying licensing agreements and related higher margins.

We project our various hardware platforms to cost between $5K and $20K, and we believe we can outperform more expensive competing products, both in performance and in simplicity and ease of use. We project additional revenue from software (SaaS subscriptions) and for certain applications, disposable sample holders. 

Applications in a Multitude of Industries 

Our applications and technology will find applications beyond traditional areas of Public Health. We anticipate that our devices will address critical analytical and detection problems in a wide range of large vertical markets.

Here’s the Total Addressable Markets (TAMS) from our initial focus markets. 

Lightsense miniaturized handheld spectrometers can be used in a variety of analysis applications with performance comparable to that of laboratory instruments, but at a dramatically lower cost, and ease of use. 

Our handheld spectrometers, both current products and instruments under development, are lightweight, easy to use, accurate, faster, and less expensive than competing technologies. We believe our technology will reach a multitude of industries.

Completed first raise, and accelerating with a second

We completed our first seed “A1” raise with SeedInvest, and will accelerate our developments with a second “A2” seed round now. 

Among our recent accomplishments, we received a Food and Beverage Magazine Award for the top 10 food safety solutions providers (Source).

The basis for the Lightsense technology portfolio has been developed by a seasoned and accomplished team over many years. Collectively, we’ve been granted over 150 patents in our careers, on a wide range of technologies.  

Currently, the Lightsense patent portfolio lineup includes:

• 7 issued or allowed patents on miniaturized spectrometers and EPS multi-spectral designs, including both Lightsense owned and exclusively licensed
• 4 patent applications
• Multiple patent applications in preparation

Providing more and sensitive data for machine learning

By focusing on new techniques for sample preparation and data analysis, as well as advances in sensors and machine learning -  we expect to enable new solutions in areas of public health with very high sensitivity and easy-to-use products that are efficient and lower cost. 

Success for us looks like ..

• Growing revenue and margin in our targeted areas, along with increased government contracts and awards to further our scientific foundations
• Having robust and profitable partnerships in 3-4 market segments that utilize our technologies in different ways

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.